BNP Paribas Financial Markets Takes $1.58 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

BNP Paribas Financial Markets bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 66,998 shares of the company's stock, valued at approximately $1,578,000. BNP Paribas Financial Markets owned 0.07% of Dyne Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of DYN. Geode Capital Management LLC lifted its holdings in Dyne Therapeutics by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock valued at $44,476,000 after acquiring an additional 27,916 shares during the period. Norges Bank acquired a new position in Dyne Therapeutics in the fourth quarter valued at approximately $22,384,000. ArrowMark Colorado Holdings LLC lifted its holdings in Dyne Therapeutics by 3.6% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 932,231 shares of the company's stock valued at $21,963,000 after acquiring an additional 32,041 shares during the period. Northern Trust Corp lifted its holdings in Dyne Therapeutics by 7.7% in the fourth quarter. Northern Trust Corp now owns 777,013 shares of the company's stock valued at $18,306,000 after acquiring an additional 55,511 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Dyne Therapeutics by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 667,452 shares of the company's stock valued at $15,725,000 after acquiring an additional 18,800 shares during the period. Institutional investors and hedge funds own 96.68% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DYN shares. JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. Chardan Capital reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 9th. HC Wainwright reduced their target price on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. BMO Capital Markets started coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price for the company. Finally, Scotiabank began coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.25.

Dyne Therapeutics Trading Down 1.8%

NASDAQ:DYN traded down $0.21 during trading hours on Friday, hitting $11.69. The company had a trading volume of 1,469,291 shares, compared to its average volume of 1,640,279. The company has a 50-day moving average of $10.32 and a 200 day moving average of $16.83. The company has a market cap of $1.33 billion, a P/E ratio of -3.28 and a beta of 1.19. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.